Denali Therapeutics

Denali Therapeutics

World Rank (Jan-05-2024)
4,587
Market Cap (Jan-05-2024)
2.812 Billion USD
World Rank (Jul-30-2023)
3,643
Market Cap (Jul-30-2023)
3.830 Billion USD
World Rank (Jan-07-2022)
3,242
Market Cap (Jan-07-2022)
5.076 Billion USD
World Rank (Jan-01-2021)
1,682
Market Cap (Jan-01-2021)
9.992 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
DNLI
Market Cap (Mar-08-2026)
3.12
Employee Count
380
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
108 Million USD
Annual Operating Income in USD
-340 Million USD
Annual Net Income in USD
-325 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
1,460 Million USD
Total Liabilities in USD
417 Million USD
Total Equity in USD
1,042 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
DENALI THERAPEUTICS INC
Yahoo
Yahoo @ Nasdaq
Company Profile

Denali Therapeutics is a Biotechnology company focused on Neurodegenerative Diseases. The headquarters is in USA.

Annual Results Summary

DENALI THERAPEUTICS - Annual Results Summary - in Million USD

Year Ending:Total RevenueOperating IncomeNet Income
Dec-2022108-340 (Loss)-325 (Loss)
Dec-202148 -295 (Loss)-290 (Loss)
Dec-20203366271
Dec-201927213 (Loss)197 (Loss)
Dec-201812946 (Loss)36 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,460 Million USD.

Total Liabilities as on Dec-2022 was 417 Million USD.

Total Equity as on Dec-2022 was 1,042 Million USD.

Founded Year
2013
IPO Year
2017
Stock Exchange
Nasdaq
Company SubCategory
Top Technology Companies in USA
Top Healthcare Companies in USA
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share